Skip to main content

US puts further squeeze on WuXi AppTec

31st May 2024

Submitted by:

Andrew Warmington

The US House of Representatives Committee on Oversight & Accountability committee has approved the Biosecure Act, which will require American companies to cease working with WuXi AppTec, among other Chinese biotechs, by 2032. This follows a vote on an earlier draft by the Senate’s Homeland Security & Governmental Affairs committee. The Act must now go through votes in both chambers and be signed into law by the President.

Also affected are WuXi Biologics, which is under different ownership to WuXi AppTec, BGI, MGI and Complete Genomics. This action is being taken on national security grounds on the basis that hostile foreign governments might misuse the health and genetic data of Amercan citizens. It also cites the danger of China entirely dominating the biotechnology supply chain.

In the first three quarters of 2023, according to investors, two thirds of WuXi AppTec's revenue came from the US market, while WuXi had 47% of its sales in North America for the whole year. Both companies have seen their share prices badly impacted by the restrictions, with WuXi Biologics seeing its fall by over 50% in 2023 and a further 36.5% in Q1 2024.

In March, the three co-CEOs of WuXi AppTec sent an open letter to customers expressing their concern about “a misguided US legislative initiative to target our company without a fair and transparent review of the facts”. While welcoming regulatory oversight, they said, “we strongly object to blanket allegations and preemptive actions against our company without due process … We are confident that upon considering the facts, US lawmakers will understand that WuXi AppTec does not in any way pose a national security risk to any country.”

The immediate effect has been to leave customers scrambling for alternative capacity elsewhere. Given that, according to CBO Yu Lu, WuXi AppTec was involved in 27% of the small molecule drugs approved by the FDA in 2023, this seems entirely plausible. There were claims that WuXi AppTec had closed, or was intending to close, a plant, but the company has since confirmed that this is not the case.

Meanwhile, another Chinese CDMO, Asymchem Laboratories, has signed a lease agreement with Discovery Park, which manages the former Pfizer plant at Sandwich, UK. This will give it its first manufacturing footprint in Europe, operating a small molecule API pilot plant and part of the development laboratories. The latter are expected to begin operation in June 2024, followed by the former in August. The site is expected to employ about 100 by the end of 2024, including many previously employed by Pfizer. Asymchm ads that it plans to add further capabilities for peptide and oligonucleotide manufacture, plus continuous flow and biocatalysis.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington